The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006.

Slides:



Advertisements
Similar presentations
Biopharmaceutical Quality
Advertisements

Patent-Extender Drugs: Loop-holes in the Law Sandy H. Yoo 4/14/06.
VALIDATION What is the new guidance?. What is a Compliance Policy Guide? Explain FDA policy on regulatory issues CGMP regulations and application commitments.
History of FDA and Related Regulatory Agencies
Chemistry, Manufacturing, and Controls (CMC) and Good Manufacturing Practices (GMPs): The Big Picture of a Long-term Commitment Elizabeth Pollina Cormier,
What’s New in the FDA’s Pharmaceutical Inspectorate and Risk Based Systems Inspection Rick Perlman Chair Food, Drug, and Cosmetic Division ASQ.
Introduction to Regulation
Overview of Drug Development: the Regulatory Process Roger D. Nolan, PhD Director, Project Operations Calvert Research Institute November, 2006 Roger D.
Development and Review Process of NDA, ANDA/AADA and OTC Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Associate Professor Department of Pharmaceutics KLE.
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
FDA Science Board Advisory Committee Meeting ORA Science Peer Review- Pesticide and Industrial Chemical Programs April 22, 2004.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
FDA’s Pharmaceutical Inspectorate Robert Coleman National Expert Drug Investigator Food and Drug Administration.
COMPARABILITY PROTOCOLS ACPS March 12-13, 2003 Stephen K. Moore, Ph.D. Chemistry Team Leader CDER/Office of New Drug Chemistry Co-Chair, Comparability.
Innovative Systems for Delivery of Drugs and Biologics Drug-Eluting Stents Current Approach to Review Ashley B. Boam, MSBE Division of Cardiovascular Devices.
The FDA Landscape AdvaMed September 2008 Judith K. Meritz
Regulation of Generic Drugs Office of Generic Drugs Craig Kiester Regulatory Support Branch.
Training Workshop on Pharmaceutical Development with a Focus on Paediatric Medicines / October |1 | Regulatory Requirement on Dossier of Medicinal.
Mrs. Brandi Robinson Office of New Animal Drug Evaluation Center for Veterinary Medicine Regulating Animal Drugs.
1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.
1 Revisions to 21 CFR Supplements and Other Changes to an Approved Application PhRMA Perspective FDA Public Meeting – 7 Feb 2007.
1 DRUG QUALITY SYSTEM FOR THE 21 ST CENTURY PQRI/FDA April CHANGES WITHOUT PRIOR APPROVAL AN FDA PERSPECTIVE Dennis M. Bensley, Jr., Ph.D. Center.
FDA’s Perspective Continued - Where We Are ?. GMP Task Groups.
What You Want to Know About Generic Drugs Generic Drugs: Safe. Effective. FDA-Approved.
Quality In Investigational Drugs Presented by: Larry Parker, BSMT (ASCP), MHSA, ASQ CQA American Society for Quality Central Arkansas Section 1407.
POSTMARKETING ADVERSE DRUG EXPERIENCE INSPECTIONAL PROGRAM CDR Thomas R. Berry, RPh FDA, Investigator RAL-RP / ATL-DO.
Overview of FDA's Regulatory Framework for PET Drugs
Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.
Carolyn Hommel Good Clinical Practice Program FDA February 25, 2004
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Industry Perspective on Challenges for Product Developers - Drugs Christine Allison, M.S., RAC Associate Regulatory Consultant, Global Regulatory Affairs.
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Investigational New Drug Application (IND)
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
FDA Focus On Consumer Protection
FDA’s Perspective on the “Pharmaceutical cGMPs for the 21st Century” Initiative David J. Horowitz, Esq. Director, CDER/FDA, Office of Compliance Advisory.
PATRICIA KERBY, MPA HUMAN SUBJECTIONS PROTECTION COMPLIANCE OFFICER OFFICE OF RESEARCH COMPLIANCE What are the FDA’s expectations in 2010?
Overview of FDA's Regulatory Framework for PET Drugs
Risk-Based CMC Review - OGD Perspective Gary J. Buehler, R.Ph. Director Office of Generic Drugs July 21, 2004 Advisory Committee for Pharmaceutical Science.
The New Drug Development Process (www. fda. gov/cder/handbook/develop
The FDA: Basic Facts It takes 12 to 15 years to develop a single drug Only 1 in 10,000 potential medications makes it completely through the process Only.
Overview of Gene Therapy Surveillance Inspections Joseph P Salewski, Chief Bioresearch Monitoring Branch CBER.
COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.
Draft Guidance for Industry: CGMPs for Phase 1 INDs Joseph C. Famulare, Director Division of Manufacturing & Product Quality Office of Compliance, CDER,
Copyright FDA Inspections: Where Do Things Go Wrong? Diana Naser RN, MS, CCRP Executive Director Clinical Research Administration Clinical Research.
1 FDA Guidance for Industry: ANDAs: Impurities in Drug Substances Published by US FDA’s Center for Drug Evaluation and Research June 2009.
FDA Office of Orphan Products Development
1 Imaging Community Critical Need #1: Standardized and Harmonized Multisite Imaging George Q. Mills, MD, MBA Vice President, Medical & Regulatory Relations.
1 Office of Pharmaceutical Science on Jon Clark FDA/CDER/OPS Associate Director for Policy Development.
Enforcement Litigation and Compliance Washington, DC December 9-10, 2015 ORA and FDA District Directors Forum Randy Pack, Director, Compliance Branch,
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.
Title Page Quality Mo Samimi, Ph.D. CMQ/OE Presented at the ASQ Biomedical Division Northern California Discussion Group. May 2011.
Comparability Protocols Nancy Sager Associate Director, QIS-Chemistry FDA/CDER/OPS.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.
FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
The Regulation on Cell Therapy Products in Japan
My Experiences as an FDA Statistician
Clinical Review Process for New Drug Development and Application

נמטוציטים משושנת ים Eli. S Lec. No.2.
Regulatory– Terms & Definitions רגולציה - מונחים והגדרות
FDA Perspective on Cardiovascular Device Development
Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.
American Society for Quality Region 5 Quality Conference
The Lifecycle of Pharmaceutical products
Overview of FDA Food Inspections
Presentation transcript:

The Role of Chemists in the FDA Drug Approval Process 231 st ACS National Meeting Atlanta, GA M. Scott Furness, Ph.D. March 26, 2006

2 Presentation Outline Introduction –FDA Organization –CDER Organization –Drug Approval Process Role of Chemistry Reviewers within CDER Role of District Investigators in the Evaluation of cGMPs with ORA

3 FDA’s Mission Statement “…… is to protect the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products.” Mission Process 1. Reviewing / Approving the drug to ensure that it is safe and effective 2.Inspecting the manufacturing facilities to ensure that the drugs are manufactured in accordance with Current Good Manufacturing Practice (cGMP) regulations.

4 FDA ORGANIZATION I. The Office of the Commissioner Associate Commissioner for International Activities and Strategic Initiatives Office of the Chief Counsel (OCC) Office of External Relations (OER) Office of Legislation (OL) Office of Management and Systems (OMS) Office of Policy/Office of Planning Office of Regulatory Affairs (ORA) Office of Science and Health Coordination (OSHC) II.Centers CDER, CBER, CDRH, CVM, CFSAN, NCTR

5 Introduction – FDA Organization 6 Centers CDER: Center for Drug Evaluation and Research –CBER: Center for Biologics Evaluation and Research –CDRH: Center for Devices and Radiological Health –CVM: Center for Veterinary Medicine –CFSAN: Center for Food Safety and Applied Nutrition –NCTR: National Center of Toxicology Research

6 Office of New Drugs (OND) –Effectiveness and Safety Office of Pharmacoepidemiology and Statistical Sciences (OpaSS) –Biostatistics and Post-marketing Safety Office of Pharmaceutical Sciences (OPS) –ONDQA, Generic Drugs, and Regulatory Research Office of Compliance Introduction – CDER Organization

7 What Do We Do in CDER? Mission –CDER assures that safe and effective drugs are available to the American people Approvals –New Drug Approval –Over The Counter Drugs –Generic Drug Approval

8 New Drug Approval: Act 505 (b) Substantial Evidence: The Basis for Approval –Evidence consisting of adequate and well-controlled investigations –Conducted by experts qualified to evaluate effectiveness –Allow conclusion that the drug will have the effect it claims

9 Requirement or Recommendation for New Drug Approval Preclinical –21 CFR IND regulations –21 CFR NDA regulations –21 CFR Labeling regulations Clinical –21 CFR adequate and well-controlled studies Guidances (FDA, ICH and Industry) Collaboration with review divisions - meetings, teleconference, and letters

10 Technical Sections Required to contain sufficient data to permit a knowledgeable approvability judgement Sections –Chemistry, manufacturing & controls (CMC) –Non-clinical pharmacology & toxicology –Human pharmacokinetics and bioavailability –Microbiology –Clinical –Statistics

11 Generic Drug Approval: Act 505 (j) Brand Name DrugGeneric Drug NDA RequirementsANDA Requirements1. Chemistry2. Manufacturing3. Controls4. Labeling5. Testing 6. Animal Studies 7. Clinical Studies6. Bioequivalence 8. Bioavailability

12 Main Types of CMC Submissions Reviewed Investigational New Drug Applications (INDs) Original New Drug Applications (NDAs) and Abbreviated New Drug Applications (ANDAs) NDA and ANDA Supplements Annual Reports Drug Master Files (DMFs)

13 Supplements -Prior Approval -CBEs (0 and 30 days) -Special (covered under 21 CFR 314) Expedited Review Catastrophic Events Post Approval Changes Guidance

14 Annual Reports -Distribution Data -Adverse Events -Labeling -Stability Data -Changes to Official Compendia -Additional Tests -Narrowing of Specifications

15 Drug Master Files (DMFs) Type 1: Facilities Type 2: Drug Substance Type 3: Containers & Closures (screw caps, glass, bottles, syringes, rubber stoppers, etc.) Type 4: Colors, Flavors, Excipients Type 5: Microbiology DMF info is proprietary and can’t be disclosed to the (A)NDA holder

16 NDA/ANDA Review Components and Composition (Drug Product) Synthesis of the Drug Substance Raw Material Controls (Active & Inactives) Manufacturing Containers and Packaging Configurations In-Process Controls Finished Dosage Form Specifications and Testing Stability (Expiration Date)

17 FDA ORGANIZATION I. The office of the Commissioner Associate Commissioner for International Activities and Strategic Initiatives Office of the Chief Counsel (OCC) Office of External Relations (OER) Office of Legislation (OL) Office of Management and Systems (OMS) Office of Policy/Office of Planning Office of Regulatory Affairs (ORA) Office of Science and Health Coordination (OSHC) II.Centers CDER, CBER, CDRH, CVM, CFSAN, NCTR

18 Evaluation of cGMPs – Inspections FDA’s Office of Regulatory Affairs (ORA) survey and inspect regulated firms in order to assess their compliance with cGMPs. cGMPs - standard guidelines set out by the FDA to ensure drug development and manufacturing is carried out in safe and quality processes, to avoid contamination and ensure repeatability.

19 ORA District Offices Central Region: Baltimore, Chicago, Detroit, Minneapolis, New Jersey, Philadelphia Pacific Region: Los Angeles, San Francisco, Seattle NE Region:New York, New England SE Region: Atlanta, Florida, New Orleans, San Juan SW Region:Dallas, Denver, Kansas Total of 18 District Offices District is responsible for conducting cGMP inspections

20 FDA Inspection Types Pre-approval Inspection (PAI) - New products (NDA & ANDA) - Major manufacturing/formulation changes - Manufacturing site changes Routine Inspection - cGMP compliance “For Cause” Inspection - Past inspection show lack of compliance - Suspicion of fraud

21 Systems Based Inspection Approach The 6 Systems: Quality System Facilities and Equipment System Material System Production System Packaging and Labeling System Laboratory Control System

22 Required Qualifications & Salaries for Chemists at the FDA CDER Chemistry Reviewers – Usually a Ph.D. is required, although highly experienced M.S. and B.S. candidates are often considered. Salary typically ranges from GS-11 ($54,272) for newly minted Ph.D.’s with no experience to GS-13 ($100,554) for highly experienced Ph.D. applicants. ORA Inspectors/Investigators – Usually a B.S. is required. Salary typically ranges from GS-9 ($44,856) to GS-12 ($84,559).

23 Summary – Chemistry Roles in FDA Drug Approval Process CDER CMC Reviewer Scientific review and analysis of data submitted in the application Assists in establishing specifications for manufacturing and control based on submitted data ORA District Investigator Conducts inspections of manufacturing sites referenced in application Assure CGMP compliance, verify authenticity and accuracy of the data in applications, and report any other data which may impact firm’s ability to manufacture the product in compliance with cGMPs

24 Thank You